Autonomix to Present Long-Term Pancreatic Cancer Pain Data at ECIO 2026

Autonomix Medical, Inc. announced it will present new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at the European Conference on Interventional Oncology (ECIO) 2026. The presentation, scheduled for April 29, 2026, will highlight long-term outcomes from the company's ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach. This addresses a significant unmet medical need for severe, difficult-to-manage pain associated with pancreatic cancer.